Shares of Exelixis, Inc. EXEL were down 23% after it announced disappointing data from the ongoing phase III study, COSMIC-312.
The study is evaluating Cabometyx in combination with Roches RHHBY Tecentriq (atezolizumab) as compared to Nexavar (sorafenib)…
